Background Inflammatory bowel disease (IBD) increases the risk of developing colon cancer. This risk is higher in men compared to women, implicating a role for female hormones in the protection against this disease. Studies from our laboratory demonstrated that estradiol (E 2 ) protects against inflammation-associated colon tumor formation when administered following chemical carcinogen and induction of chronic colitis. Aim This study seeks to better understand the effect of E 2 on acute colitis in the presence and absence of estrogen receptor b (ERb). Methods Inflammation was induced by 2,4,6-trinitrobenzenesulfonic acid in wild-type (WT) and ERb knockout (ERbKO) mice implanted with a control or E 2 -containing pellet and killed 5 days later. Inflammation and injury were scored by a pathologist. Apoptosis and proliferation were assessed by immunohistochemistry. Cytokines were measured by multiplex analysis. Results E 2 treatment reduced inflammation in the middle colon in WT mice and the distal colon in ERbKO mice compared to control mice. WT mice had reduced IL-6, IL-12, IL-17, GM-CSF, IFN-c, MCP-1, MIP-1a, and TNF-a, and ERbKO had reduced IL-6 and IFN-c expression in response to E 2 . Injury scores were lower in E 2 -treated ERbKO mice compared to control ERbKO mice. ERbKO mice had increased proliferation in the basal third of crypts in the distal colon and decreased apoptosis in the proximal colon. Conclusions These data suggest that E 2 has differential protective effects against acute colitis in the presence or absence of ERb and provide insight into how E 2 may protect against IBD.
Introduction
Inflammatory bowel disease (IBD) affects over one million people in the USA. Typically, IBD occurs in persons in their twenties and thirties at which point symptoms lesson for a number of years followed by flare-ups of the disease later in life. The two primary forms of IBD, Crohn's disease and ulcerative colitis, both confer a greater lifetime risk of developing colon cancer [1, 2] . This increased risk is most likely due to an increased rate of growth due to the exposure to pro-inflammatory cytokines. Interestingly, women have been observed to be 60% less at risk than men to develop inflammation-associated colon cancer, suggesting that female hormones may play a role in the prevention of this disease [3] .
A number of experimental models have demonstrated that estrogens have anti-inflammatory properties in tissues other than the intestine and one way in which estradiol (E 2 ), the most biologically active form of estrogen in the human body, may be protecting against inflammation-associated colon carcinogenesis is through the suppression of intestinal inflammation [4] [5] [6] [7] . Epidemiological studies have observed that pre-menopausal women with Crohn's disease reported a worsening of their IBD-related symptoms during menses, the time during the estrous cycle that E 2 concentrations are at their lowest [8] . Not only does this suggest that E 2 could be protecting against intestinal inflammation, but the fact that the same worsening of symptoms was not observed in women with ulcerative colitis suggests that the role of E 2 in protecting against inflammation could be dependent on the subtype of IBD.
Experimental data to support the protective effects of E 2 on the development of inflammation-associated colon tumors, however, are conflicting. Data from our laboratory indicate that treatment with E 2 in mice following induction of inflammation-associated colon cancer using cotreatment with the colon-specific carcinogen azoxymethane (AOM) and dextran sulfate sodium (DSS) was effective at reducing both the number and size of colon tumors [9] . Other groups, however, have observed that in mice pre-treated with E 2 and then subjected to AOM/DSS, polyp number and size were increased [10] . In a separate study investigating the role of estrogen receptor (ER)b in AOM/DSSinduced polyp formation in the presence of endogenous E 2 levels, Saleiro et al. determined that mice lacking ERb (ERbKO) had more polyps at 9 weeks compared to wildtype (WT) littermates. This study further saw an induction of pro-inflammatory cytokines in the absence of ERb at 16 weeks; however, at 9 weeks, no significant differences in cytokine expression were detected [11] .
The disparity in the observed results is not limited to eventual tumor development. Studies investigating the effects of E 2 solely on inflammation have also reached varying data. Here though, the incongruent findings are likely the result of the models of inflammation used. Studies using DSS as the inflammatory agent found that E 2 worsened disease severity, whereas colitis induced by dinitrobenzene sulfonic acid was improved in the presence of E 2 [10, 12] . When 2,4,6-trinitrobenzenesulfonic acid (TNBS) was used to induce colonic inflammation in rats, estradiol benzoate and the phytoestrogen genistein improved pathological scores in models of acute and chronic inflammation, respectively [13, 14] . DSS and TNBS induce inflammation through distinct mechanisms resulting in colitis that resembles ulcerative colitis and Crohn's disease, respectively, and the differences in response to E 2 observed between these two models may be reflective of distinct effects of E 2 on these two separate forms of IBD.
The focus of the present study is to investigate the physiological actions of E 2 during acute TNBS-induced colitis in WT and ERbKO mice. While previous studies suggest that estrogen is protective against TNBS colitis, the mechanism behind this protection is still poorly understood. Studies in our laboratory in both sporadic and inflammation-associated colon cancer models suggest that ERb, the primary ER in the colon, mediates the protective effect of E 2 in this tissue [9, 15] . To date, however, the role of ERb in TNBS-induced colitis is unknown. Understanding the function of E 2 and ERb during acute inflammation is important, particularly when you take into consideration the fact that persons with active Crohn's disease have lower colonic expression of ERb compared to when their disease is in remission [16] .
Methods and Materials Animals
C57Bl6/J mice heterozygous for ERbKO (±) were originally obtained from the Jackson Laboratory. The mice were housed at the Laboratory Animal Resources and Research Facility at Texas A&M University. Mice were bred to produce WT and ERbKO offspring, and genotype was confirmed using genomic tail DNA. All procedures were performed under a protocol approved by the Institutional Animal Care and Use Committee at Texas A&M University.
Induction of Colitis
While it does not perfectly recapitulate human Crohn's disease, TNBS-induced colitis shares many characteristics with human Crohn's disease including the involvement of NOD2, the macroscopic pattern of inflammation, induction of mucosal edema, crypt distortion, and abscess formation [17] .
For this study, female mice were weight and age matched (mean 27.8 g and 5.8 months) and divided into treatment groups (n = 12-16 mice per group). On day 1, mice were ovariectomized (OVX) and implanted with either a 20-mg cholesterol containing pellet or a 0.5-mg E 2 ? 19.5-mg cholesterol (Sigma-Aldrich, St. Louis, MO) pellet subcutaneously and placed on a phytoestrogen-free diet. Corresponding plasma E 2 levels for the groups at the end of the study were 1.2 nM in the mice receiving E 2 and undetectable in the cholesterol mice with no significant differences between genotype and TNBS treatment group. Two weeks after surgery and pellet implant, mice were pretreated with 1% TNBS dermal absorption through the skin on their backs. One week following pre-treatment, a 2.5% TNBS solution was administered intrarectally 2-4 cm into the colon using a flexible plastic gavage tube (Instech Solomon) after a 12-h fast. Mice were killed 5 d postintrarectal TNBS. Colons were resected and longitudinally bisected. One half of the colon was rolled into a Swiss roll and fixed in PFA. The other half was snap-frozen in liquid nitrogen for cytokine analysis. Inflammation and injury in the colons were assessed by a board-certified pathologist on H&E-stained colon Swiss rolls on a scale of 0-3. In brief, a score of 0 would indicate no inflammation or injury noted, while a score of 3 would indicate severe inflammation or injury.
Cytokine Multiplex Analysis
Snap-frozen colon tissues representative of the whole colon were homogenized in 1 mL Tissue Protein Extraction Reagent (Thermo Scientific). Total protein content was assessed using the DC Protein Assay (Bio-Rad) as per the manufacturer's instructions. The Magnetic Mouse Cytokine/Chemokine Milliplex Map Kit was used to measure tissue levels of IL-6, IL-10, IL-12(p40), IL-17, GM-CSF, IFN-c, MCP-1, MIP-1a, and TNF-a following the manufacturer's instructions. All samples were diluted to 10 M. In brief, 25 lL diluted sample was added per well of a 96-well plate in addition to 25 lL assay buffer and 25 lL of the magnetic beads provided in the kit. The plate was sealed and agitated on a plate shaker overnight at 4°C. The following day, the 96-well plate was placed on a handheld magnet, the contents of the wells removed, and then the plate was washed twice. Following washing, 25 lL of detection antibodies was added to each well and the plate was incubated at room temperature for 1 h with agitation. Next, 25 lL of streptavidin-phycoerythrin was added to each well and the plate was incubated at room temperature for half an hour with agitation. The plate was then washed twice, the magnetic beads resuspended in 150 lL Luminex sheath fluid, and the plate was run on a Luminex 200.
Terminal Deoxynucleotidyl Transferase-Mediated dUTP Nick End Labeling Assay
Paraffin-embedded, paraformaldehyde (PFA)-fixed colon Swiss rolls were rehydrated, and the ApopTag Peroxidase In Situ Apoptosis Detection Kit (Millipore; Billerica, MA) was used for the terminal deoxynucleotidyl transferasemediated dUTP nick end labeling (TUNEL) assays following the manufacturer's instructions with slight modifications. PFA-fixed tissues were rehydrated and treated with 10 lg/mL proteinase K for 3 min at 37°C. Endogenous peroxidase activity was blocked using 0.3% H 2 O 2 in methanol for 30 min. Tissues were incubated at room temperature (RT) for 20 s in equilibration buffer and then incubated for 1 h at 37°C in reaction buffer plus TDT enzyme. The TDT enzyme was omitted from an individual section as a negative control for the stain. Subsequently, slides were placed in stopwash solution for 10 min followed by 30 min at RT in anti-digoxigenin in a humidified chamber. A 0.5% DAB solution for 20 s was used as the chromogen, and nuclei were counterstained in 0.5% methyl green for 5 s. Lastly, slides were dehydrated and coverslipped.
Immunohistochemistry for BrdU
Four micrometer sections were taken from the PFA-fixed tissues. Sections were deparaffinized and rehydrated. Endogenous peroxidase was quenched using 3% H 2 O 2 in methanol for 30 min, and antigen retrieval was achieved by microwaving in 10 mM citrate buffer for 20 min. Slides were then incubated in the primary antibody, anti-BrdU (Roche, Basel, Switzerland) diluted 1:20 at 4°C overnight in a humidified chamber. During each stain, the primary antibody was left off of a single slide to serve as a negative control. The following morning, the slides were washed and then incubated in the secondary antibody, goat antimouse HRP (Abcam, Cambridge, MA) diluted 1:250. Meyer's hematoxylin was used as the counterstain. Lastly, slides were dehydrated and coverslipped.
Immunohistochemistry Analysis
The TUNEL and BrdU assays were analyzed in the same manner. For each, 20 well-oriented crypts per animal from both the distal and proximal colon were symmetrically bisected and the right halves of each were analyzed. The total number of positively stained cells was divided by the total number of cells in the crypt column to generate the percentage of apoptotic or proliferative cells for each crypt column.
Statistics
Analysis for all data was determined using one-way ANOVA or Student's t test using JMP Pro 10. Differences were considered significant if P \ 0.05.
Results

E 2 Protects Against TNBS-Induced Weight Loss and Increases Colon Length
All four groups of mice had a significant weight loss from their pre-study weights. WT control mice lost significantly more weight than WT E 2 -treated mice. There was no difference in weight loss between ERbKO mice in response to E 2 (Fig. 1a) . Additionally, as it has been routinely observed in our laboratory, E 2 treatment increased the length of the colon in WT but not ERbKO mice (Fig. 1b) .
E 2 Protects Against Inflammation and Injury in Regions of the Colon
After induction of acute colitis using TNBS, E 2 -treated WT mice had reduced inflammation in the middle region of the colon. ERbKO mice had reduced inflammation in response to E 2 in the distal end of the colon (Fig. 2a) . There were no changes in injury scoring in the WT mice for any region of the colon. In ERbKO E 2 -treated mice, however, a reduction in injury was observed in the proximal, distal, and overall colon compared to ERbKO control-treated mice (Fig. 2b) .
E 2 Reduces the Expression of Pro-inflammatory Cytokines
Cytokine expression profiles were determined using a multiplex magnetic bead assay. In WT mice, treatment with E 2 resulted in reduced expression of IL-6, IL-12(p40), IL-17, GM-CSF, IFN-c, MCP-1, MIP-1a, and TNF-a. In ERbKO mice, IL-6 and TNF-a expression was significantly downregulated by E 2 . Several other cytokines, IL-12(p40), GM-CSF, MCP-1, MIP-1a, and TNF-a, trended toward reduced expression in response to E 2 in ERbKO mice; however, the differences did not reach statistical significance (Fig. 3) . 
Proliferation Is Increased in ERbKO Mice
Proliferation was assessed by BrdU incorporation into actively dividing cells. Both the proximal and distal ends of the colon were analyzed. The crypts were further divided into bottom, middle, and top regions. No changes in proliferation were observed in either genotype in response to E 2 in the proximal colon for any region in the crypt (Fig. 4a) . In the distal colon, E 2 -treated ERbKO mice had increased proliferation compared to control-treated ERbKO mice in the bottom third of crypts. No other significant differences were observed in the distal colon (Fig. 4b) .
Apoptosis Is Decreased in ERbKO Mice
Apoptosis was analyzed in the proximal and distal colon using a TUNEL assay. Again, the crypts were divided into bottom, middle, and top regions to observe changes in the different populations of colonocytes. In the proximal colon, E 2 -treated ERbKO mice had reduced apoptosis both overall and in the top third of colon crypts compared to control ERbKO mice (Fig. 5a ). There was a trend for increased apoptosis in E 2 -treated ERbKO mice in the distal colon compared to ERb controls; however, no significant changes occurred in the distal colon in response to E 2 in any region of the crypt for either genotype (Fig. 5b) . TNFα pg/mL pg/mL pg/mL pg/mL pg/mL pg/mL pg/mL pg/mL pg/mL 
Discussion
Epidemiological studies suggest that E 2 is protective against inflammation-associated colon tumor formation [3] . One mechanism by which this protection may occur is through the modulation of acute inflammatory episodes in the colon. Thus far, however, results from in vivo studies investigating the effects of E 2 on inflammation and subsequent tumor formation in colon cancer models have been inconclusive. The differences observed in response to the presence of E 2 may be due, in part, to the inherent differences in the pathology of each disease as well as the variety of models used to study them. This study utilized TNBS to mimic acute Crohn's disease inflammation. In this model, E 2 was observed to protect against inflammation in WT and ERbKO mice in the middle and proximal regions of the colon, respectively. The likely mediator of the reduced inflammation in the middle and distal colon in WT and ERbKO E 2 -treated mice, respectively, is the decreased expression of pro-inflammatory cytokines observed in the presence of E 2 . Aberrant expression of cytokines is a hallmark for Crohn's disease, and several of the current therapies are aimed at blocking cytokine activity [18] . Highlighting the fact that E 2 has varying effects depending on ERb expression, cytokine production was reduced in both WT and ERbKO mice; however, only expression of two of the targets analyzed, IFN-c and IL-6, was significantly downregulated in the ERbKO mice compared to the eight cytokines affected in the WT mice. Studies have shown that macrophages express ERb and that ERb-specific agonists can influence cytokine production [19, 20] . The lack of ERb expression in the ERbKO mice reduces the ability of these cells to respond to E 2 and might partially explain the reduced physiological effects observed in these mice in regard to cytokine production.
While the ERbKO mice lack ERb, they still express ERa and other, non-classical, ERs such as G protein-coupled estrogen receptor 1 (GPER or GPR30). Other studies have observed that ERa-specific agonists influence leukocyte rolling and adhesion to protect against sepsis in the colon, demonstrating that ERa has a protective roll in the tissue [21] . GPER has also been implicated in mitigating inflammation; treatment of endothelial cells with a GPERspecific agonist has been demonstrated to reduce the expression of pro-inflammatory cytokines [22] . It is also important to note that the colonic inflammatory process is complex and does not rely solely on the colonic epithelia but is rather a systemic process with immune cells migrating into the tissue upon initiation of the inflammatory cascade. Unlike the colonic epithelia, ERb is not necessarily the primary ER in these immune cells. In human monocytes, Pelekanou et al. observed expression of GPER and ERa36, a splice variant of ERa, but they did not detect any expression of ERb or full-length ERa. Furthermore, they demonstrated that in these cells, E 2 treatment inhibited LPS-induced IL-6 inflammatory response and this could be inhibited by the addition of either the nuclear ER antagonist ICI or the GPER-specific antagonist G15 [23] . Another study observed GPER expression in mast cells in human colon biopsies. Contrary to the protective effects of E 2 in the colon observed in our study, this group correlated increased GPER expression in mast cells to enhanced abdominal pain severity in diarrhea-predominant irritable bowel syndrome patients [24] . Together, these studies suggest that ERa36 and/or GPER has a role in inflammation and in the colon. Being as the ERbKO mice in our study retain ERa and GPER expression, it is possible that these estrogen receptors are responsible for the antiinflammatory effects of E 2 observed in our model. While it goes beyond the scope of the presented study, ongoing experiments in our laboratory are investigating the contribution of immune cells as well as GPER and ERa and its variants in response to E 2 in both acute and chronic colitis.
Injury scores were also reduced by E 2 treatment. For all groups, injury scoring was highest in the distal colon, possibly a result of the intrarectal method of TNBS administration: Insertion of the gavage tube into the colon physically damages this portion of the tissue which is a limitation as to how data from this model may be compared to Crohn's disease in humans. However, due to the physical damage, the results observed in response to E 2 in the distal colon in regard to injury are partially reflective of wound healing and not solely inflammation. E 2 treatment was associated with a lower injury score in ERbKO mice in the proximal, distal, and overall colon. In the distal colon, in addition to the reduction in injury, an increase in proliferation was observed in ERbKO mice. This increase in proliferation could be indicative of damaged colonocytes being replaced and may be the underlying mechanism behind the increased healing in the distal colons of these mice resulting in reduced injury scores. Future studies will explore the timing of E 2 exposure with the goal to clearly define its potential role in wound healing in the colon.
The fact that the protection against inflammation was observed in different regions of the colon for WT and ERbKO animals and that injury was only reduced in the presence of E 2 in ERbKO mice suggests that during acute inflammation separate mechanisms of protection are being utilized for different regions of the colon in the presence and absence of ERb. The proximal and distal colon is distinct in developmental origin, morphology, and gene expression profiles [25] [26] [27] . Additionally, the microbial population also varies between regions of the colon, due in part to changes in the viscosity of the mucus allowing for different microbes to reach the mucosa [28] . These physiological variances between regions of the colon support the hypothesis that the mechanism of action of E 2 differs between the proximal, middle, and distal colon.
Overall, data from this study suggest that E 2 is partially protective against acute TNBS-induced colitis and reduces the expression of pro-inflammatory cytokines in the colon. This protective effect differs between WT and ERbKO mice in regard to location of protection against inflammation, injury, and the cytokine expression profiles. This suggests unique actions of E 2 in the presence and absence of ERb which has clinical relevance due to the reduced ERb expression in the colon of people with active Crohn's disease. Furthermore, reduction of acute inflammation could be a contributing mechanism by which E 2 reduces the risk of inflammation-associated colon cancer. 
